Cargando…
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined...
Ejemplares similares
-
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
por: Zhang, Yang, et al.
Publicado: (2022) -
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
por: Zhang, Yang, et al.
Publicado: (2022) -
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
por: Rahmani, Nora E., et al.
Publicado: (2021) -
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
por: Matre, Polina, et al.
Publicado: (2016) -
P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES
por: Senapati, Jayastu, et al.
Publicado: (2023)